The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Guardant Health; Janssen; Lilly; Merck KGaA; Novocure; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Urania Dafni
Honoraria - F. Hoffmann LaRoche
Expert Testimony - AstraZeneca
 
Anthony Pope
Research Funding - MSD (Inst)
 
Susana Cedres Perez
Consulting or Advisory Role - Amphera; Bristol-Myers Squibb; MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech; Roche/Genentech
 
Riyaz N.H. Shah
Honoraria - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EQRx (Inst); Guardant Health (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
(OPTIONAL) Uncompensated Relationships - ALK; British Thoracic Oncology Group; EGFR Positive UK; Roy Castle Lung Cancer Foundation
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Laura Cove Smith
No Relationships to Disclose
 
Reyes Bernabe Caro
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; MSD Oncology; Roche; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Martin Früh
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Takeda (Inst)
Speakers' Bureau - Pfizer (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); BMS (Inst)
 
Kristiaan Nackaerts
No Relationships to Disclose
 
Laurent Greillier
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; MSD; Pfizer; Roche
 
Amina Scherz
No Relationships to Disclose
 
Bartomeu Massuti
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Janssen; Merck Serono; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche; Sanofi/Regeneron
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; MSD Oncology; Roche
 
Saemi Schaer
No Relationships to Disclose
 
Spasenija Savic Prince
No Relationships to Disclose
 
Heidi Roschitzki-Voser
No Relationships to Disclose
 
Barbara Ruepp
No Relationships to Disclose
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Illumina (Inst); Imedex (Inst); Incyte (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President
 
Rolf A. Stahel
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; F. Hoffmann LaRoche
Consulting or Advisory Role - AstraZeneca; Eisai; F. Hoffmann LaRoche; Gilead Sciences; GlaxoSmithKline; Guardant Health; Janssen; Merck; Merck Sharp & Dohme; Novocure; Pfizer; PharmaMar
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; F. Hoffmann LaRoche